ARNA - アリ―ナ・ファ―マシュ―ティカルズ （Arena Pharmaceuticals Inc.）

Pfizer stock rose near its 50-day line Friday after the drug giant wrapped its $6.7 billion takeover of biotech Arena Pharmaceuticals.

Source: [[https://pixabay.com/photos/laboratory-apparatus-equipment-217041/ Pixabay]] Pfizer announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Read more… |

Shares of Pfizer Inc. were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year. Pfizer''s stock has gained 45.0% over the past year, while the broader S&P 500 is up 10.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Pfizer (PFE) confirmed that the HSR waiting period for its planned purchase of Arena Pharmaceuticals (ARNA) expired on Wednesday.The $6.7B acquisition of Arena (ARNA) is now expected…

Arena Pharmaceuticals (ARNA) rose 1.1% in after hours trading after a Nasdaq delisting notice indicated the company''s last trading day would be Thursday due to the completion of its sale…

Pfizer stock rose near its 50-day line Friday after the drug giant wrapped its $6.7 billion takeover of biotech Arena Pharmaceuticals.

Source: [[https://pixabay.com/photos/laboratory-apparatus-equipment-217041/ Pixabay]] Pfizer announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Read more… |

Shares of Pfizer Inc. were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year. Pfizer''s stock has gained 45.0% over the past year, while the broader S&P 500 is up 10.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Pfizer (PFE) confirmed that the HSR waiting period for its planned purchase of Arena Pharmaceuticals (ARNA) expired on Wednesday.The $6.7B acquisition of Arena (ARNA) is now expected…

Arena Pharmaceuticals (ARNA) rose 1.1% in after hours trading after a Nasdaq delisting notice indicated the company''s last trading day would be Thursday due to the completion of its sale…

Nuveen Asset Management LLC increased its holdings in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 21.7% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 511,497 shares of the biopharmaceutical companys stock after purchasing an additional 91,083 shares during the period. Nuveen Asset Management LLCs holdings in Arena Pharmaceuticals were worth $34,885,000 as []

Atom Investors LP bought a new position in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,350 shares of the biopharmaceutical companys stock, valued at approximately $569,000. Several other institutional investors and hedge funds []

Arena Pharmaceuticals (NASDAQ:ARNA) will issue its quarterly earnings data after the market closes on Thursday, November 4th. Analysts expect the company to announce earnings of ($2.42) per share for the quarter. Parties that are interested in participating in the companys conference call can do so using this link. Arena Pharmaceuticals (NASDAQ:ARNA) last issued its quarterly []